NCT05742126View on ClinicalTrials.gov

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dosed of HSK36273 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

September 12, 2022

Study Completion Date

September 15, 2022

Conditions
Healthy
Interventions
DRUG

HSK36273

Multiple continuous IV infusion ascending doses for 5 days

DRUG

Placebo

Matching placebo

DRUG

Heparin sodium injection

Matching positive control

Trial Locations (1)

Unknown

the Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY